Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)
A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Accesso esteso
Accesso esteso
A disposizione
- Disponibile: l'accesso esteso è attualmente disponibile per questo trattamento sperimentale e i pazienti che non partecipano allo studio clinico potrebbero essere in grado di accedere al farmaco, al biologico o al dispositivo medico in fase di studio.
- Non più disponibile: l'accesso esteso era disponibile per questo intervento in precedenza, ma non è attualmente disponibile e non sarà disponibile in futuro.
- Temporaneamente non disponibile: l'accesso esteso non è attualmente disponibile per questo intervento, ma dovrebbe esserlo in futuro.
- Approvato per il marketing: l'intervento è stato approvato dalla Food and Drug Administration degli Stati Uniti per l'uso da parte del pubblico.
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Abbotsford, British Columbia, Canada
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
-
-
-
-
-
Frankfurt, Germania
-
Heidleberg, Germania
-
Jena, Germania
-
Magdeburg, Germania
-
Ulm, Germania
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti
-
Montgomery, Alabama, Stati Uniti
-
-
Arizona
-
Tucson, Arizona, Stati Uniti
-
-
California
-
La Jolla, California, Stati Uniti
-
Oceanside, California, Stati Uniti
-
Orange, California, Stati Uniti
-
Palo Alto, California, Stati Uniti
-
Roseville, California, Stati Uniti
-
-
Colorado
-
Golden, Colorado, Stati Uniti
-
-
Florida
-
Clearwater, Florida, Stati Uniti
-
Gainesville, Florida, Stati Uniti
-
Hialeah, Florida, Stati Uniti
-
Jacksonville, Florida, Stati Uniti
-
North Miami Beach, Florida, Stati Uniti
-
Sarasota, Florida, Stati Uniti
-
Winter Park, Florida, Stati Uniti
-
-
Georgia
-
Marietta, Georgia, Stati Uniti
-
Savannah, Georgia, Stati Uniti
-
-
Illinois
-
Chicago, Illinois, Stati Uniti
-
-
Indiana
-
Bloomington, Indiana, Stati Uniti
-
-
Kansas
-
Topeka, Kansas, Stati Uniti
-
-
Kentucky
-
Bowling Green, Kentucky, Stati Uniti
-
Louisville, Kentucky, Stati Uniti
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti
-
-
Maryland
-
Annapolis, Maryland, Stati Uniti
-
-
Massachusetts
-
Newton, Massachusetts, Stati Uniti
-
-
Michigan
-
Chesterfield, Michigan, Stati Uniti
-
Dearborn, Michigan, Stati Uniti
-
Troy, Michigan, Stati Uniti
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti
-
-
Mississippi
-
Ocean Springs, Mississippi, Stati Uniti
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti
-
Mexico, Missouri, Stati Uniti
-
-
New York
-
New York, New York, Stati Uniti
-
Syracuse, New York, Stati Uniti
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti
-
Charlotte, North Carolina, Stati Uniti
-
Raleigh, North Carolina, Stati Uniti
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti
-
Cleveland, Ohio, Stati Uniti
-
Dayton, Ohio, Stati Uniti
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti
-
-
Texas
-
Austin, Texas, Stati Uniti
-
Irving, Texas, Stati Uniti
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti
-
-
Vermont
-
Burlington, Vermont, Stati Uniti
-
-
Virginia
-
Chesapeake, Virginia, Stati Uniti
-
Richmond, Virginia, Stati Uniti
-
-
Washington
-
Seattle, Washington, Stati Uniti
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti
-
Milwaukee, Wisconsin, Stati Uniti
-
Monroe, Wisconsin, Stati Uniti
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men and women
- Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)
Exclusion Criteria:
- Active or draining fistula present at screening
- Lactating and/or pregnant female subjects
- A history of any health condition that could potentially interfere with the disease and/or the treatment
- A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product
- Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study
- History of drug or alcohol abuse in the prior year
- Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
|
Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
|
|
Sperimentale: Certolizumab pegol 400 mg
|
Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38
Lasso di tempo: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
|
Week 38
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Subjects With Continuous Remission Off Steroids at Week 38
Lasso di tempo: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A subject with continuous remission off steroids at Week 38 is a subject in remission (CDAI =< 150) from the visit when he stops taking steroids to Week 38 and is off corticosteroids until Week 38.
|
Week 38
|
|
Cumulative Percentage of Subjects With Relapse/Treatment Failure at Week 38
Lasso di tempo: Week 38
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
Week 38
|
|
Time to Relapse/Treatment Failure During the 38-week Double-blind Treatment Period
Lasso di tempo: During the 38-week double-blind treatment period
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
During the 38-week double-blind treatment period
|
|
Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Lasso di tempo: Over the 38-week double-blind treatment period
|
The median weekly dose of corticosteroids is calculated for each subject, and these per-subject median values are further summarized by treatment group.
The mean of the per-subject median doses in each treatment group is presented here.
|
Over the 38-week double-blind treatment period
|
|
Per-subject Cumulative Dose of Corticosteroids Over the 48-week Study Period
Lasso di tempo: Over the 48-week study period
|
The cumulative dose of corticosteroids over the 48-week study period is calculated for each subject individually.
The mean of these values for each treatment group is presented here.
|
Over the 48-week study period
|
|
Change From the 6-week run-in Period in Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Lasso di tempo: 6-week run-in period, 38-week double-blind treatment period
|
The run in period lasted a minimum of 1 week and a maximum of 6 weeks.
During this period subjects were treated with any dose or type of systemic corticosteroids the Investigator felt was appropriate.
To be eligible for study randomization, subjects must have been in remission (CDAI ≤150 points) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Subjects who did not meet these criteria were not randomized and were withdrawn from the study.
|
6-week run-in period, 38-week double-blind treatment period
|
|
Crohn's Disease Activity Index (CDAI) Score at Week 38
Lasso di tempo: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 38
|
|
Change From Baseline in CDAI Score at Week 38
Lasso di tempo: Week 0, Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 0, Week 38
|
|
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Lasso di tempo: Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher score indicates a better quality of life.
IBDQ remission is defined as a subject having an IBDQ total score >= 170 points.
|
Week 38
|
|
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Lasso di tempo: Week 0, Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher scores indicates a better quality of life.
IBDQ response is defined as an increase from baseline in the IBDQ total score >= 16 points.
|
Week 0, Week 38
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- C87059
- 2006-003870-88 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .